Research News
Research That Matters – NEIDL: Right Place, Right Time
Original article from BU Annual Report. January 31, 2022 Microbiologist Robert Davey’s ongoing novel coronavirus research was boosted with $400,000 through Harvard from the Massachusetts Consortium on Pathogen Readiness, part of $1.6 million in funding that BU researchers received. When news broke that an unknown and dangerous virus had reached US shores... More
BU Scientists Are Prepared to Detect Omicron—and Other Variants
Original article from The Brink By Kat J. McAlpine. December 8, 2021 BU’s National Emerging Infectious Diseases Laboratories (NEIDL) has been monitoring COVID-19 variants from BU and Boston Medical Center tests since February When will the coronavirus variant known as Omicron arrive at BU? Although it’s hard to predict, it seems like... More
Malaria Vaccine—the First Ever to Immunize against a Parasitic Infection—Gets Green Light from WHO (Q&A w/ Davidson Hamer)
Original article from The Brink By Jessica Colarossi. October 7, 2021 Malaria and infectious disease expert says the vaccine could save countless children’s lives in sub-Saharan Africa—but he still has a few concerns In a historic move, the World Health Organization (WHO) on Wednesday announced their recommendation for widespread use of the... More
MED’s Biology of the Lung Funded through Its 50th—Yes, 50th—Year
Original article from BU Today By Joel Brown. September 23, 2021 BU’s longest running federally funded training program began in 1975 When the School of Medicine training program called Biology of the Lung: A Multidisciplinary Program began, on July 1, 1975, Gerald Ford was president, all four Beatles were alive, and gas... More
We work with dangerous pathogens in a downtown Boston biocontainment lab – here’s why you can feel safe about our research
Original article from The Conversation by Ronald Corley. July 14, 2021 Microbiologist Ronald Corley has gone to work every day throughout the pandemic as director of the National Emerging Infectious Diseases Laboratories. Within this secure lab facility in Boston, scientists study pathogens as diverse as tuberculosis, Ebola virus, yellow fever virus... More
Study Reveals Recipe for Even More Powerful COVID-19 Vaccines
Original article from The Brink by Kat J. McAlpine. June 11, 2021 NEIDL, Broad scientists say next-generation vaccines could stimulate another arm of the immune system, imparting better protection against coronavirus variants A new study looking at the way human cells activate the immune system in response to SARS-CoV-2 infection could open... More
Nahid Bhadelia to Head New BU Center for Emerging Infectious Diseases
Original article from BU Today by Doug Most. May 18, 2021 Will connect policy with research and use lessons from Ebola and COVID to prepare lawmakers and the public for next crisis The first-floor classroom is empty inside the Boston University School of Medicine on a gray and chilly May morning in... More
COVID-19 Vaccines and Variants Explained (video)
Original article from The Brink by Devin Hahn. April 14, 2021 In this video, BU public health experts discuss the future of the pandemic as vaccines ramp up while viral variants become more prevalent Over 50 million Americans have been fully vaccinated against COVID-19, yet even as more and more people roll... More
Study provides novel platform to study how SARS-CoV-2 affects the gut
Original article from Medical XPress by BU School of Medicine. April 13, 2021 How could studying gastrointestinal cells help the fight against COVD-19, which is a respiratory disease? According to a team led by Gustavo Mostoslavsky, MD, Ph.D., at the BU/BMC Center for Regenerative Medicine (CReM) and Elke Mühlberger, Ph.D., from... More
Pfizer and BioNTech say vaccine prevents Covid-19 in adolescents
Original article from STAT by Matthew Herper. March 31, 2021 Pfizer and BioNTech said Wednesday that their Covid-19 vaccine prevented symptomatic disease and was well-tolerated in a Phase 3 study of adolescents ages 12 to 15. The companies say they will submit the data to the Food and Drug Administration as an... More